Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 studyFranco Locatelli, Cristina Díaz de Heredia, Yoshiyuki Takahashi et al.|The Lancet Haematology|2024Cited by 18
S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDYFranco Locatelli, Cristina Díaz de Heredia, Bülent Antmen et al.|HemaSphere|2023Cited by 3